Press

NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company“) today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,000,000 common shares (or pre-funded warrant in lieu thereof), series A common warrants to purchase up to 1,000,000 common shares and short-term series…

TORONTO, Dec. 20, 2024 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce its financial and operational results for the year ended August 31,…

SAN FRANCISCO – Jaguar Health, Inc.(NASDAQ: JAGX) (‘Jaguar’) today announced that Magdalena Biosciences, Inc. (‘Magdalena’), a joint venture formed by Jaguar and Filament Health Corp. (OTCQB: FLHLF)(Cboe CA: FH)(FSE: 7QS) (‘Filament’ or ‘Filament Health’), successfully completed an import of six kilograms of coca leaf from Peru to Filament’s Metro Vancouver research and development facility. This is the second import of coca leaf into Canada that Magdalena has…

NEW YORK, December 17, 2024 — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today highlighted recent progress that has been made with its active Phase IIb clinical trial of nature derived psilocybin, in conjunction with psychotherapy, as a potential treatment for Adjustment Disorder following a life-limiting cancer diagnosis in Palliative Care. To…